Classifications

• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/02—Nutrients, e.g. vitamins, minerals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2200/00—Function of food ingredients
  • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
  • A23V2200/332—Promoters of weight control and weight loss

Definitions

• the present invention relates to the regulation of fat or lipid metabolism by means of compositions and diets which are high in resistant starch and unsaturated fats.
• Dietary starch an important component of human carbohydrate intake, is composed of two types of glucose polymer, namely amylose and amylopectin.
• Amylose is a linear polymer of glucose residues linked by ⁇ 1-4) bonds whereas amylopectin is a branched polymer of glucose residues linked by ⁇ (1-4) and ⁇ (l-6) bonds.
• the present inventors have now shown that consumption of a diet high in resistant starch and unsaturated fats or lipids results in desirable effects on carbohydrate and fat metabolism. Specifically, it has been shown that consumption of a diet high in resistant starch and unsaturated fats or lipids leads to reduced post-prandrial plasma glucose concentrations after meal intake, as well as lower plasma insulin levels; a reduction in plasma leptin concentrations together with an increase in satiety; and a decrease in the levels of lipid deposition in white adipose tissue, brown adipose tissue and muscle tissue together with an increase in glycogen synthesis in the liver.
• the present invention provides in a first aspect, a method for regulating carbohydrate and fat metabolism in an individual which method comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.
• a method for enhancing fat metabolism in an individual which method comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.
• the enhancement of fat metabolism includes a reduction in fat accumulation and/or an increase in fat oxidation.
• a method of treating an individual suffering from obesity comprises replacing at least 5% of the individual ' s daily carbohydrate intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.
• a method of lowering the risk of obesity in an individual comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.
• a method of lowering the risk of non-insulin dependent diabetes mellitus in an individual comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.
• (6) a method of reducing the post-prandial plasma glucose and/or insulin levels in an individual following food consumption by the individual which method comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.
• a method of controlling an individual's body fat composition which method comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 10% of the individual's saturated fat intake with unsaturated fat.
• the present invention provides a method of preparing a foodstuff for use in a method according to the first aspect which method comprises substituting constituents with a low resistant starch content with constituents with a high resistant starch content and substituting some or all of the saturated fats with unsaturated fats.
• the present invention provides a composition comprising at least 2g of resistant starch and at least 2g of unsaturated fat wherein the resistant starch is present in a proportion of at least 5% by weight of the total starch content.
• the unsaturated fat is present in a proportion of at least 25% by weight of the total fat content.
• the unsaturated fat is selected predominantly from poly- unsaturated fats, with a good balance between omega-3 and omega-6 types, and mono-unsaturated fats.
• the composition may, for example, be in the form of a tablet, a foodstuff, a component of a prepackaged meal or a component of a calorie- controlled diet.
• the present invention provides a method for regulating carbohydrate and fat metabolism in an individual which method comprises administering to the individual a composition of the invention.
• a method of lowering the risk of non-insulin dependent diabetes mellitus in an individual comprises administering to the individual a composition of the invention.
• a method of reducing the post-prandial plasma glucose and/or insulin levels in an individual following food consumption by the individual comprises administering to the individual a composition of the invention.
• the present invention also provides a composition of the invention for use in a method according to the fourth aspect of the invention.
• the present invention further provides the use of a composition of the invention in the manufacture of a medicament for use in a method according to the fourth aspect of the invention.
• the present invention also provides a method of enhancing fat utilisation in a diet of an individual, the method comprising consuming in a given meal at least 2 gof resistant starch with the fat to be utilised.
• the present invention further provides a method of lowering the incidence of obesity in an individual through the stimulation of increased levels of fat oxidation, the method comprising placing the individual on a high carbohydrate diet, rich in resistant starch to stimulate increased levels of fat oxidation in the individual.
• a method for lowering the incidence of non-insulin dependent diabetes mellitus in an individual comprising placing the individual on a high carbohydrate diet, rich in resistant starch, to stimulate increased levels of fat oxidation in the individual.
• compositions and foodstuffs are provided.
• the present invention provides compositions comprising high levels of resistant starch and unsaturated fat.
• resistant starch includes those forms defined as RSl, RS2, RS3 and RS4 as defined in Brown. McNaught and Moloney (1995) Food Australia 47: 272-275. Either modified or unmodified resistant starches or mixtures thereof can be used in the present invention. A particular resistant starch can be the product of multiple modifications. Modified resistant starches include breakdown products such as resistant maltodextrins.
• resistant starch particularly suitable for the present invention is starch containing resistant starch.
• the starches have an amylose content of at least 40% [w/w). although the amylose content of the starch may vary depending on the plant species from which the starch has been obtained.
• the starch is from maize having an amylose content of at least 70% (w/w). at least 80% (w/w) or at least 90% [w/w).
• the starch can also be chemically, physically, or enzymically treated or modified. Chemical modification can be by oxidation, cross-bonding, etherification, esterification, acidification, dextrinisation, or mixtures thereof. Physical modification includes heat-moisture treatment,
• the resistant starches are derived or obtained from maize
• starch corn
• cereals like sorghum, wheat, barley, oats, triticale, maize and rice, tubers like potatoes and tapioca, legumes such as peas, and others including starches derived from conventional inbred breeding techniques or from genetically modified plant species.
• Starches can also be treated to enhance the resistant starch content by a number of physical or chemical means. Where the starch has been obtained from non-genetically modified plant species, the resulting treated starch can still be termed non-GMO resistant starch. For a number of reasons relating to the regulation of GMO foods and consumer preference, it may be desirable to use only non-GMO starch, whether treated or untreated, in compositions of the invention.
• One preferred treatment means is to heat-treat starch in the presence of moisture (heat-moisture treatment) which can be achieved by a number of processes including heating under negative, atmospheric or positive pressure under elevated moisture, or cycling techniques through different temperatures and pressures. Heating can be in the order of 100 to 180°C, preferably around 120 to 150°C and moisture levels of 10 to 80%, preferably 20 to 60%. Repeated autoclaving and rapid cooling can also be used to increase the resistant starch content of starches. It will be appreciated that these processes and conditions can be changed to achieve the desired increase in the level of resistant starch in the starch being treated.
• Treatment can also be by solvent extraction to remove fats and/or minerals from the starch.
• high amylose starches are disclosed which are resistant starches and include maize starch having an amylose content of 50% (w/w) or more, particularly 80% (w/w) or more, rice starch having an amylose content of 27% ⁇ -w/w) or more, or a wheat starch having 35% [w/w] o ⁇ more.
• This invention is not, however, limited to these forms of resistant starch.
• other forms of resistant starch can be derived from sources such as bananas and tubers such as potatoes and modified forms thereof.
• the resistant starch is derived from maize, sorghum, rice. barley, oats, triticale, wheat, legumes, potato, or banana starches.
• amylose content of some starches appears to be related to the resistant starch content, one preferred embodiment is the use of starches having an amylose content of at least 40% (w/w).
• Resistant starch obtained or derived from maize starch has been found to be particularly suitable for the present invention. In many starch-containing plants, the amylose content does not need to increase to the high levels found in maize in order for them to demonstrate the properties of resistant starch.
• the amount of resistant starch can be demonstratd by the resistance of the starch granule or starch derived material to attack by amylases. irrespective of its amylose content. However, the amylose content can act as an indicator of whether the starch granule will exhibit this property of resistance to amylolysis.
• Maize starches having an amylose content of at least 70% ⁇ w/w), at least 80% (w/w) or at least 90% [w/w) are preferred as these starches contain high levels of starch granules forming resistant starch.
• unsaturated fats includes unsaturated fatty acid esters in both solid and liquid form.
• fats. oils, fatty acids and lipids are used interchangeably herein.
• the fat is a mono-unsaturated fat, a poly-unsaturated fat, an omega-3 fat, or an omega 6 fat.
• Further vegetable triglycerides relevant to the present invention include those obtained from seeds, beans, fruits, nuts and other plant materials, often obtained by mechanical expelling and/or solvent extraction. Examples which are particularly suitable for use in the present invention are sunflower oil including high and mid oleic varieties, soybean oil, cottonseed oil, canola or rapeseed oil including low linolenic and other modified varieties, flax or linseed oil including high linolenic varieties [Linola], maize or corn oil, olive oil, peanut oil, rice bran oil, palm oil and fractionated palm oils, palm kernel oil. coconut oil and the like.
• Triglycerides of animal origin can be used in the present invention and include those obtained from milk and from the processing of cattle, sheep and fish.
• Preferred examples include n-3 polyunsaturated fatty acids (PUFAs) and n-6 PUFAs. such as fish oils.
• compositions according to the present invention comprise high levels of resistant starch and high levels of unsaturated fat as a proportion of carbohydrate/fat content compared with typical foodstuffs and dietary supplement.
• compositions of the present invention comprise at least 2g of resistant starch and 2g of unsaturated fat.
• compositions may comprise at least 5, 10, 15 or 20g of resistant starch. Since one of the aims of the present invention is to replace dietary starch of the non-resistant type, such as amylopectin starch, with resistant starch, it is preferred that the resistant starch is present as a significant proportion of the total starch content of the composition.
• the resistant starch may be present in a proportion of at least 10% by weight of the total starch content, preferably at least 15, 20, 25, 30. 35, 40, 50, 60, 70 or 80% by weight of the total starch content.
• resistant starch is present as a significant proportion of the total carbohydrate content of the composition.
• the resistant starch may be present in a proportion of at least 5% by weight of the total carbohydrate content, preferably at least 10, 15, 20, 25, 30. 35, 40. 50, 60 or 75% by weight of the total carbohydrate content.
• Types of resistant starch that may be included in the compositions are described above.
• compositions typically comprise at least 2g of unsaturated fat or its equivalent.
• compositions may comprise at least 3, 4. 5, 6 or 8g of unsaturated fat [higher for food spreads such as margarine]. It is preferred to include unsaturated fat such that the ratio of resistant starch to unsaturated fat is from about 1:1 to 1:2, although the ratio can be markedly different for an individual food which is used in the context of the diet of an individual.
• the unsaturated fat is present as a significant proportion of the total fat content of the composition.
• the unsaturated fat may be present in a proportion of at least 25% by weight of the total fat content, preferably at least 35, 50, 75 or 80% by weight of the total starch content.
• saturated fat is substantially absent from the composition. Types of unsaturated fat that may be included in the compositions are described above.
• compositions may further comprise carbohydrate sources other than resistant starch, saturated fats, flavouring agents, vitamins, minerals, electrolytes, trace elements and other conventional additives. Proteins, particularly proteins resistant to digestion and termed “by-pass proteins or resistant proteins", may also be included to ensure optimal physiological performance or utilisation. If any of these optional ingredients are not present in the composition of the invention, they should normally be supplied as a supplement to the composition of the invention in other elements of the diet, so that an adequate supply of all essential nutritional ingredients is ensured. If the composition of the invention is intended to supply a substantial part of the food intake of a subject, the optional ingredients are preferably present, so that separate intake thereof can be avoided. This is of particular importance for overweight or obese subjects on a weight reduction treatment, by which it is important that all essential nutritional ingredients are supplied in recommended amounts.
• Vitamins and minerals may be added to-the composition in accordance with the limits laid down by health authorities.
• the composition of the invention may comprise all recommended vitamins and minerals.
• the vitamins will typically include A, Bl, B2, B12, folic acid, niacin, panthotenic acid, biotin, C, D, E and K.
• the minerals will typically include iron, zinc, iodine, cobber, manganese, chromium and selenium.
• Electrolytes, such as sodium, potassium and chlorides, trace elements and other conventional additives are also added in recommended amounts.
• the composition of the invention may take any form which is suitable for human or animal consumption, such as a foodstuff or drink.
• the composition is a powdery mixture which is soluble, suspendable. dispersible or emulsifiable in a water-containing liquid such as water, coffee, tea or fruit juice.
• the composition may be packed in a package intended for covering the total nutrition requirement for a defined period of time, such as three days or a week, whereby the composition will be divided into suitable sub-units of a daily dose, preferably four to five sub-units for women and four to six sub-units for men per daily dosage, which are packed separately before being packed into the package, or the package will be provided with means for aportioning of such sub-units.
• the composition of the invention is a liquid nutritrional preparation in a water-containing liquid, in which the solid ingredients are dissolved, suspended, dispersed or emulsified in an amount of
• liquid nutritional preparation When the liquid nutritional preparation is intended for drinking, it will usually comprise a flavouring agent as discussed above.
• composition of the invention may be in the form of a solid composition such as a nutritional bar, fruit bar, cookie, or a bakery product such as cake, bread or muffin, or a dairy product such as a low- fat spread or margarine.
• Compositions may form part or all of a prepackaged meal, included chilled and frozen ready-made meals.
• compositions may also be formulated as tablets. Since the quantities of resistant starch and unsaturated fat as well as other ingredients such as binders and flavouring agents result in compositions of at least 7 to 8g, the tablets may be relatively large. Consequently, the tablets will typically be formulated such that they can be chewed prior to swallowing. Alternatively, the compositions may be subdivided into a number of tablets.
• compositions of the invention may be provided, for example, in the form of consumer meals, drinks, powders, tablets, health foods, nutritional supplements and animal feeds.
• compositions may form all or part of a calorie controlled diet, for example a calorie-controlled diet having an energy content of from 800 to 1200 kcal per day, or more than 1200 kcal per day. such as more than 2000 kcal per dav.
• compositions of the invention and foodstuffs high in resistant starch and unsaturated fats are intended as a partial or full replacement for the carbohydrate and fat intake in the normal diet of individuals.
• One method of achieving the necessary replacement is to provide nutritional supplements together with a reduction in quantities of food or particular food items in the existing diet of an individual.
• Another method is to provide normal food items in which the carbohydrate and fat content and composition has been modified to provide a foodstuff with increased levels of resistant starch and unsaturated fat (and lower levels of non-resistant starch carbohydrate and saturated fat).
• the present invention provides a method for producing a composition of the invention which method comprises replacing (i) some or all of the carbohydrate content of a foodstuff or drink with resistant starch and (ii) some or all of the saturated fat content of a foodstuff or drink with unsaturated fat.
• the present invention also provides a method of preparing a foodstuff which method comprises substituting one or more food components with one or more food components that have a higher resistant starch content and substituting some or all of the saturated fats with unsaturated fats so as to increase the proportion of resistant starch, increase the proportion of unsaturated fats and lower the proportion of saturated fats.
• the resistant starch content is increased to at least 5% by weight of the total carbohydrate content of the foodstuff or composition, more preferably at least 10. 20. 30, 40. 50 or 70% by weight.
• the unsaturated fat content is increased to at least 20% by weight of the total fat content of the foodstuff or composition, more preferably at least 30. 40. 50. 60. 70. 80. 90. 95 or 100% by weight.
• the above foodstuffs or compositions may be prepared using normal food manufacturing techniques known in the art relevant to any particular foodstuff or composition.
• the amount of resistant starch in currently available white bread is about 1% by weight and the amount of fat (mainly as polyunsaturated fatty acids) is about 2.5% by weight.
• the resistant starch content of bread may be increased to from 6 to 12% by weight.
• the amount of fat may be increased to at least 6% in normal white bread (and up to at least 30% in speciality foods).
• An object of the present invention is to modify the diet of an individual by increasing their resistant starch intake together with substituting saturated fats with unsaturated effects to achieve the desired metabolic effects.
• the levels of resistant starch and unsaturated fats, such as polyunsaturated fatty acids may be increased as compared with the individual's existing dietary intake.
• the proportion of resistant starch relevant to total dietary carbohydrate intake and the proportion of unsaturated fats such as polyunsaturated fatty acids relative to total dietary fat intake may be increased.
• This manipulation of an individual's diet may be achieved either by a total diet approach or by a single food approach where compositions of the invention rich in resistant starch and unsaturated fats are administered.
• the increased levels of resistant starch may be provided by one food or food group and the increased levels of unsaturated fats such as polyunsaturated fatty acids may be provided by another food or food group.
• a bakery product such as bread, which has been specifically formulated to be high in resistant starch may be provided together with a dairy spread formulated to be high in polyunsaturated fatty acids.
• the desired metabolic effects include reduced post-prandrial plasma glucose concentrations after meal intake, as well as lower plasma insulin levels; a reduction in plasma leptin concentrations together with an increase in satiety: and a decrease in the levels of lipid deposition in white adipose tissue, brown adipose tissue and muscle tissue together with an increase in glycogen synthesis in the liver.
• c-fos transcription is an indicator of neuronal activity (Xin et al., 2000. Brain Research Bulletin, 52: 235-242). Since these regions of the brain are known to play a role in the regulation of energy balance and satiety, the observation that transcriptional activity/neuronal activity in these regions is affected by dietary changes is important. Furthermore, these results are consistent with the changes in satiety and plasma leptin concentrations seen when the resistant starch and fat content of the diet is altered.
• the present invention aims to provide methods for regulating carbohydrate and fat metabolism as well as methods for regulating the mechanisms that regulate satiety.
• an individual may be placed on a diet such that in the combined meals, the combined meals contain at least 10 grams of resistant starch or at least 5 grams higher than a comparable meal containing a high quantity of readily digestible starches. It has been found that the consumption of at least 15 grams, preferably at least 20 grams, and more preferably around 30 grams total resistant starch per day with meals provides an improved fat metabolism of fat, namely increased oxidation of dietary fats and/or mobilisation and utilisation of stored fats, in an individual.
• the high carbohydrate diet rich in resistant starch provides approximately 50% (it may be higher or lower) of the available calories from carbohydrate, with at least 5 g, preferably 10 g, more preferably at least 20 g, even more preferably at least 25 g, and most preferably at least 30 g resistant starch per day.
• the consumption of at least 5 g of resistant starch, preferably at least 10 g in a single meal will also have a beneficial effect by increasing fat oxidation.
• the diet may also comprise an increased proportion of unsaturated fats.
• the amount of unsaturated fat in the diet is such that at least 50% of the available calories from fat are provided by the unsaturated fat. more preferably at least 70%.
• Respiratory Quotient is the molar ratio of carbon dioxide (C0 2 ) produced to oxygen (0 2 ) consumed and this ratio varies depending on the energy source being utilised by the body.
• RQ when oxidising carbohydrate as the sole energy source is theoretically 1.00.
• RQ when oxidising lipids as the sole energy source is theoretically 0.71.
• Mixed diets will produce RQs which vary between these two theoretical values.
• the results shown herein demonstrate that the RQ is lowered in individuals consuming a diet high in resistant starch (see Figure 13). This indicates that the resistant starch is causing a shift in fuel mobilisation that favours fat oxidation over carbohydrate oxidation.
• the present invention provides a method for regulating carbohydrate and fat metabolism in an individual which method comprises replacing at least 5% of the individual's daily carbohydrate intake with resistant starch and at least 20% of the individual ' s saturated fat intake with unsaturated fat.
• At least 7. 10. 20, 30. 40. 50 or 60% of the individual's daily carbohydrate intake is replaced with resistant starch.
• Preferably at least 5, 7, 10, 20, 30, 40, 50, 60 or 70% of the individual's daily saturated fat intake is replaced with unsaturated fat.
• the present invention also provides method for regulating carbohydrate and fat metabolism in an individual which method comprises providing at least 5% of the individual's daily carbohydrate intake as resistant starch and at least 60% of the individual's fat intake as unsaturated fat.
• the amount of resistant starch provided as a proportion of daily carbohydrate intake is in the range from 5 to 90%, preferably from 10 to
• the amount of resistant starch is at least 5%, typically from 5 to 45%, preferably from 5 to
• the amount of unsaturated fat provided as a proportion of daily fat intake is in the range from 60 to 95%, preferably at least 60, 70, 80 or
• the amount of unsaturated fat is at least 15%. typically from 15 to 30%, such as at least 20 or 30% of the total diet based on calorie content.
• compositions and methods of the invention may be used to achieve one or more of the following:
• An enhancement of fat utilisation in an individual for example a reduction in fat accumulation (in white adipose tissue, brown adipose tissue and/or muscle tissue), and/or an increase in fat oxidation (which may be evidenced by a reduction in RQ).
• a lowering of the incidence or risk of obesity in an individual A lowering of the incidence or risk of obesity in an individual:
• Body shaping An improvement in energy utilisation during exercise such as sports activities e.g. to improve sports performance.
• the present invention is applicable for animals and humans by manipulating the diet through feed, food, supplements and pharmaceuticals.
• the present invention is typically applicable to all age ranges, such as prepubescents, young adults (18 to 24 years of age), middle aged adults (from about 35 to 50) and older adults (over 50 years of age).
• prepubescents young adults (18 to 24 years of age
• middle aged adults from about 35 to 50
• older adults over 50 years of age.
• the precise nature of the diet will vary according to the symptoms, risk factors, objective of treatment and age of the individual concerned and can be readily determined by a dietician, physician or other suitably qualified person.
• FIG. 3 Incremental area under the curve (AUC) for a) glucose and b) insulin in response to meals of different amylose concentration.
• AUC area under the curve
• LH lateral hypothalamus
• VH ventromedial hypothalamic nucleus
• PVH para ventricular hypothalamic nucleus
• Arc arcuate hypothalamic nucleus
• DH dorsomedial hypothalamic nucleus
• Figure 13 Change in RQ in response to resistance starch in the diet. Two weeks after commencing a DS or RS diet (day 14), subjects returned for a follow-up fasting blood sample and a 3 hour meal test.
• Rats were provided with standard rat chow for one week before surgical implantation of canulae. Canulations were then performed one week prior to conducting the acute meal tests. One week post canulation, rats were fasted overnight. The following morning, the rats were presented with one gram carbohydrate /kg body weight and post-prandial blood samples were taken over a 2 hour period. Two hours after eating, the rats were sacrificed and their tissues were harvested for later analysis.
• Table 1 Diet composition of acute meals.
• Offspring of lab bred rats were injected at 2 days of age with Streptozotocin, to induce a non-insulin diabetic condition, or with standard buffer solution. At 8 weeks of age, the rats were fasted overnight and given a glucose tolerance test to determine their diabetic state. Rats were divided into diabetic or non-diabetic groups and fed test diets for 8 weeks. Metabolic rates were obtained on each rat at week 7 of the feeding period. Upon completion of feeding, glucose tolerance tests were repeated and blood samples obtained. Rats were then sacrificed and brains and muscle tissues were harvested for later analysis.
• Rats were provided with standard rat chow for one week before surgical implantation of canulae. Canulations were then performed one week prior to conducting the acute meal tests. One week post canulation, rats were fasted overnight. The following morning, animals were presented with one gram carbohydrate per kg body weight. After eating, rats were injected with radioactive marker and post-prandial blood samples were taken over a 2 hour period.
• the effect of diet on neuronal (c-fos) activity is quite interesting, when looking at its impact on total energy balance.
• the lateral hypothalamus (LHA) is thought to be the feeding center within the parasympathetic system, which is associated with positive energy balance.
• the ventromedial hypothalamus (VMH) is considered the satiety centre of the sympathetic nervous system and represents negative energy balance.
• Figure 6 illustrates that diets high in unsaturated fats and resistant starch have decreased activation of the hunger centre (LHA) and increased levels of activation of the satiety center, whereas diets high in saturated fat and low in resistant starch have the opposite effect. When taken together (LHA/NMH), these values determine total energy balance.
• Figures 7 through 12 illustrate the effect of resistant starch on the glycogen synthesis/utilisation and lipid synthesis/oxidation of various tissues, following ingestion of starches of different concentration
• Figures 7 and 9 show significant differences in the rate of lipogenesis within brown adipose and white adipose tissues and a trend toward increased glycogenesis within liver tissue. This confirms that consumption of resistant starch, especially long-term, may in fact shift substrate utilisation from glycogen to fat oxidation.
• Leptin levels leptin is a protein synthesized in adipose tissue and is thought to inhibit food intake and increase satiety. Leptin receptor is found in the hypothalamus of the brain and mav be a kev link between the neuronal (c-fos) and hormonal systems and their effect on caloric homeostasis.
• Figure 5 shows significant differences only between groups with different starch concentrations, although there was a trend toward higher leptin levels in the unsaturated fat group. Differences between the starch groups can be explained by the large difference in body and fat weights of the animals, as there was substantial weight loss with chronic resistant starch consumption. This weight loss could be attributed, in part, to the substrate utilisation shift we noted in the absortion study. Also, with the fat loss will be a decrease in leptin production.
• Subjects were randomly divided into two groups. The first group received a traditional starch (TS) diet, low in resistant starch, whereas the second group received a Hi-maize TM (HM) diet, high in resistant starch.
• the TS diet consisted of standard commercially available products whereas the HM diet consisted of commercially available product containing [Hi-maizeTM (Table 1).
• TS group mean and SEM values for age. height and weight were 22.3 + 0.6 years. 180 +_3.1 cm. and 73.5 + 3.7 kg, respectively.
• HM group mean and SEM values for age, height and weight were 23.5 +_ 0.6 years, 185 +_ 1.8 cm. and 74.1 +_ 2.4 kg. respectively.
• a fasting venous blood sample (antecubital) was taken from each subject followed by a diet history interview and thorough explanation of the dietary guidelines for the study. Two weeks after commencing the diet (day 14). subjects returned for a follow- up fasting blood sample and a 3 hour meal test.
• the test meal was either TS or HM, based upon the subject's diet over the two week study period, and consisted of 60g breakfast cereal, 250 ml Lite White milk, 1 slice of bread (toasted), 1 muffin (toasted), 10 g of Canola margarine and 20 g of jam.
• Venous blood samples (antecubital) were taken 30, 60, 120 and 180 min post-ingestion of the test meal.
• Respiratory quotient (RQ) measurements were taken at 0, 60. 120 and 180 min after ingestion of the test meal using a Datex Delta trac II (Helsinki, Finland). In addition, all blood samples were analysed for serum glucose, serum insulin, plasma cholesterol, plasma total lipid and plasma free fatty acid concentration.
• Resistant starch consumption caused an acute increase in fat oxidation.
• consumption of a high carbohydrate diet irrespective of resistant content, lowered fasting plasma FFA concentrations.
• these results indicate that a high carbohydrate diet, rich in resistant starch may be beneficial for those who suffer metabolic diseases in which plasma FFA oversupply is symptomatic such as obesity and non-insulin dependent diabetes mellitus.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Diabetes (AREA)
• Nutrition Science (AREA)
• General Health & Medical Sciences (AREA)
• Mycology (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Food Science & Technology (AREA)
• Polymers & Plastics (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Pediatric Medicine (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Child & Adolescent Psychology (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Plant Substances (AREA)
• Medicinal Preparation (AREA)
• Polysaccharides And Polysaccharide Derivatives (AREA)
• Edible Oils And Fats (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Grain Derivatives (AREA)
• Jellies, Jams, And Syrups (AREA)

Priority Applications (13)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=3820828

Family Applications (1)

Country Status (20)

Cited By (2)

Families Citing this family (17)

Citations (5)

Family Cites Families (12)

• 2000
  • 2000-04-06 AU AUPQ6733A patent/AUPQ673300A0/en not_active Abandoned
• 2001
  • 2001-04-06 BR BR0109960-4A patent/BR0109960A/pt not_active IP Right Cessation
  • 2001-04-06 CN CNB018107478A patent/CN100435665C/zh not_active Expired - Lifetime
  • 2001-04-06 US US10/009,023 patent/US20030045504A1/en not_active Abandoned
  • 2001-04-06 KR KR1020027013433A patent/KR20020090229A/ko not_active Ceased
  • 2001-04-06 WO PCT/AU2001/000392 patent/WO2001076394A1/en not_active Ceased
  • 2001-04-06 AT AT01919008T patent/ATE387861T1/de not_active IP Right Cessation
  • 2001-04-06 ES ES01919008T patent/ES2305063T3/es not_active Expired - Lifetime
  • 2001-04-06 CA CA002405012A patent/CA2405012A1/en not_active Abandoned
  • 2001-04-06 MX MXPA02009879A patent/MXPA02009879A/es not_active Application Discontinuation
  • 2001-04-06 JP JP2001573922A patent/JP2003529616A/ja active Pending
  • 2001-04-06 EP EP01919008A patent/EP1267642B1/en not_active Expired - Lifetime
  • 2001-04-06 PT PT01919008T patent/PT1267642E/pt unknown
  • 2001-04-06 NZ NZ521416A patent/NZ521416A/en unknown
  • 2001-04-06 HK HK03104598.5A patent/HK1052618A1/zh unknown
  • 2001-04-06 DK DK01919008T patent/DK1267642T3/da active
  • 2001-04-06 DE DE60133093T patent/DE60133093T2/de not_active Expired - Lifetime
• 2002
  • 2002-10-01 ZA ZA200207891A patent/ZA200207891B/en unknown
  • 2002-10-02 NO NO20024722A patent/NO20024722L/no not_active Application Discontinuation
  • 2002-11-01 CR CR6807A patent/CR6807A/es not_active Application Discontinuation
• 2003
  • 2003-07-15 US US10/619,794 patent/US20040058890A1/en not_active Abandoned
• 2012
  • 2012-07-30 JP JP2012168848A patent/JP2013010762A/ja active Pending

Patent Citations (5)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events